Compare DBL & BNTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | DBL | BNTC |
|---|---|---|
| Founded | 2011 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 268.9M | 313.9M |
| IPO Year | 2011 | 2020 |
| Metric | DBL | BNTC |
|---|---|---|
| Price | $13.75 | $8.81 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $24.33 |
| AVG Volume (30 Days) | 154.2K | ★ 197.1K |
| Earning Date | 01-01-0001 | 11-13-2026 |
| Dividend Yield | ★ 8.67% | N/A |
| EPS Growth | N/A | ★ 6.67 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.94 | $8.00 |
| 52 Week High | $15.70 | $16.76 |
| Indicator | DBL | BNTC |
|---|---|---|
| Relative Strength Index (RSI) | 55.89 | 41.76 |
| Support Level | $12.94 | $8.52 |
| Resistance Level | $14.45 | $14.09 |
| Average True Range (ATR) | 0.21 | 0.67 |
| MACD | 0.06 | 0.10 |
| Stochastic Oscillator | 97.62 | 39.20 |
Doubleline Opportunistic Credit Fund operates as a closed-end management investment company. Its investment objective is to seek a high total investment return by providing a high level of current income and the potential for capital appreciation. The Fund invests in debt securities, residential and commercial mortgage-backed securities, asset-backed securities, U.S. Government securities, corporate debt, international sovereign debt, and short-term investments.
Benitec Biopharma Inc is a clinical-stage biotechnology company focused on advancing novel genetic medicines. Its technology could provide a one-shot cure for a wide range of diseases that require strict, ongoing treatment regimens or have no effective treatment or only palliative care options. The Company is developing a silence-and-replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life-threatening genetic disorder. The company has a single operating segment, which is the business of discovery and development of therapeutic agents for the treatment of genetic disorders.